Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 2 , Pages 127-134, June 2007

Standard and Low-dose Hormone Therapy for Postmenopausal Women—Focus on the Breast

Department of Obstetrics and Gynecology, Taipei Veteran General Hospital, and National Yang-Ming University School of Medicine, Taipei, Taiwan

Accepted 12 January 2007.

Article Outline

Summary 

Menopause occurs naturally when the ovary ceases folliculogenesis, or artificially by surgical and/or medical ablation of the ovarian function. Menopause is a hypoestrogenic state, which may adversely affect estrogen target tissues, such as the brain, skeleton and skin, as well as the cardiovascular and genitourinary systems, with resultant frequency and severity of climacteric symptoms. The climacteric symptoms, however, vary significantly among women. For decades, hormone therapy (HT) has been the mainstay and is considered the most effective for managing menopausal symptoms. The prolonged use of either single estrogen therapy or a combination therapy of estrogen and progestogen (EPT) might be associated with a slightly increased risk of breast cancer and many resultant adverse events, such as coronary heart disease, stroke and venous thromboembolism. Perhaps because the clear benefits are limited to these end points of HT in treating menopausal women, the relatively significant adverse event profiles of these women may not be enough to trigger primary care physicians to be more aggressive than they have been to date in treating climacteric symptoms of postmenopausal women. However, severe climacteric symptoms really disturb the woman's life. Some epidemiologic studies have shown that the increased risk for breast cancer after 5 years of combined EPT is similar in magnitude to other lifestyle variables, such as 10-year delayed menopause, fewer pregnancies and reduced breastfeeding, postmenopausal obesity, excessive alcohol or cigarette use, and lack of regular exercise. Furthermore, elevated serum concentrations of either endogenous or exogenous (replaced by HT) sex hormone in either pre- or postmenopausal women are associated with an increased risk of breast cancer. Finally, the increased breast cancer risk diminishes soon after discontinuing hormones, and largely disappears by 5 years after cessation. Taken together, low-dose conventional HT can be used with symptomatic menopausal women, but is worthy of further evaluation because we found the following potential benefits, including (i) low-dose oral EPT appears to be effective for the alleviation of climacteric symptoms; (ii) it has a good tolerability profile with a low incidence of the most common and problematic side effects, such as breast tenderness and an increased mammographic density. Altogether, when compared with the standard dose HT, physicians may prefer to use low-dose HT initially in managing the climacteric symptoms of postmenopausal women. Time will prove.

Key Words:  estrogen , hormone therapy , low-dose , menopause , postmenopausal women , progestins

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Rowe T , Blake J , Belisle S . Introduction. Canadian Consensus Conference on Menopause, 2006 update . J Obstet Gynaecol Can . 2006;28(Special Edition 1):S13–S20
  2. Wang PH , Cheng MH , Chao HT , Chao KC . Effects of tibolone on the breast of postmenopausal women . Taiwan J Obstet Gynecol . 2007;46:121–126
  3. Practice Committee of the American Society for Reproductive Medicine  . Estrogen and progestogen therapy in postmenopausal women . Fertil Steril . 2006;86(Suppl 1):S75–S88
  4. Chao KC, Wang PH, Yen MS, Chang CY, Juang CM, Twu NF, et al. New selective tissue estrogenic activity regulator (STEAR) in menopausal therapy in Taiwan . Taiwanese J Obstet Gynecol . 2005;44:327–331
  5. Practice Committee of the American Society for Reproductive Medicine  . The menopausal transition . Fertil Steril . 2006;86(Suppl 1):S253–S256
  6. ESHRE Capri Workshop Group  . Hormones and breast cancer . Hum Reprod Update . 2004;10:281–293
  7. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer . Lancet . 1997;350:1047–1059
  8. Collins JA , Blake JM , Crosignani PG . Breast cancer risk with postmenopausal hormonal treatment . Hum Reprod Update . 2005;11:545–560
  9. Ferreira E , Brown TER . Therapeutics: prescription drugs . J Obstet Gynaecol Can . 2006;28(Special edition 1):S61–S67
  10. Loose-Mitchell DS , Stancel GM . Estrogens and progestins . In:  Hardman JG ,  Limbird LE ,  Gilman AG editor. Goodman & Gilman's The Pharmacological Basis of Therapeutics . 10th editionxs. Toronto: McGraw-Hill; 2001;p. 1597–1637
  11. van de Weijer PH , Mattsson LA , Ylikorkala O . Benefits and risks of long-term low-dose oral continuous combined hormone therapy . Maturitas . 2007;56:231–248
  12. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins . Maturitas . 2003;46(Suppl 1):S7–S16
  13. Sitruk-Ware R . Progestins in the menopause . J Steroid Biochem Mol Biol . 1999;69:185–193
  14. Graziottin A . Libido: the biologic scenario . Maturitas . 2000;34(Suppl 1):S9–S16
  15. Sitruk-Ware R . Pharmacological profile of progestins . Maturitas . 2004;47:277–283
  16. Lobo RA . Absorption and metabolic effects of different types of estrogens and progestogens . Obstet Gynecol Clin North Am . 1987;14:143–167
  17. Palacios S , Foidart JM , Genazzani AR . Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism . Maturitas . 2006;55:297–307
  18. Desindes S , Belisle S , Graves G . Menopause and age-related concerns . J Obstet Gynaecol Can . 2006;28(Special edition 1):S21–S32
  19. MacLennan A , Lester S , Moore V . Oral oestrogen replacement therapy versus placebo for hot flushes . Cochrane Database Syst Rev . 2001;1:CD002978
  20. Barnabei VM , Cochrane BB , Aragaki AK , Nygaard I , Williams RS , McGovern PG , et al.   Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative . Obstet Gynecol . 2005;105:1063–1073
  21. Samsioe G . Transdermal hormone therapy: gels and patches . Climacteric . 2004;7(4):347–356
  22. Utian WH , Shoupe D , Bachmann G , Pinkerton JV , Pickar JH . Relief of vasomotor symptoms and vaginal atrophy with low doses of conjugated equine estrogens and medroxyprogesterone acetate . Fertil Steril . 2001;75:1065–1079
  23. Rodstrom K , Bengtsson C , Lissner L , Milsom I , Sundh V , Bjorkelund C . A longitudinal study of the treatment of hot flushes: The population study of women in Gothen-burg during a quarter of a century . Menopause . 2002;9:156–161
  24. Crandall C . Low-dose estrogen therapy for menopausal women: a review of efficacy and safety . J Womens Health . 2003;12:723–747
  25. Cherry N , Gilmour K , Hannaford P , Heagerty A , Khan MA , Kitchener H , et al.   Oestrogen therapy for prevention of rein-farction in postmenopausal women: a randomised placebo controlled trial . Lancet . 2002;360:2001–2008
  26. Hodis HN , Mack WJ , Azen SP , Lobo RA , Shoupe D , Mahrer PR , et al.   Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women . N Engl J Med . 2003;349:535–545
  27. Viscoli CM , Brass LM , Kernan WN , Sarrel PM , Suissa S , Horwitz RI . A clinical trial of estrogen-replacement therapy after ischemic stroke . N Engl J Med . 2001;345:1243–1249
  28. Stefanick ML , Anderson GL , Margolis KL , Hendrix SL , Rodabough RJ , Paskett ED , et al.   Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy . JAMA . 2006;295:1647–1657
  29. Nachtigall LE , Nachtigall RH , Nachtigall RD , Beckman EM . Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems . Obstet Gynecol . 1979;54:74–78
  30. Angerer P , Stork S , Kothny W , Schmitt P , von Schacky C . Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial . Arterioscler Thromb Vasc Biol . 2001;21:262–268
  31. Hulley S , Furberg C , Barrett-Connor E , Cauley J , Grady D , Haskell W , et al.   Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II) . JAMA . 2002;288:58–66
  32. Chlebowski RT , Hendrix SL , Langer RD , Stefanick ML , Gass M , Lane D , et al.   Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial . JAMA . 2003;289:3243–3253
  33. Writing Group for the Women's Health Initiative Investigators  . Risks and benefits of estrogen plus progestin in healthy postmenopausal women . JAMA . 2002;288:321–333
  34. Beral V . Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study . Lancet . 2003;362:419–427
  35. Kaaks R , Berrino F , Key T , Rinaldi S , Dossus L , Biessy C , et al.   Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) . J Natl Cancer Inst . 2005;97:755–765
  36. Missmer SA , Eliassen AH , Barbieri RL , Hankinson SE . Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women . J Natl Cancer Inst . 2004;96:1856–1865
  37. Tworoger SS , Missmer SA , Barbieri RL , Willett WC , Colditz GA , Hankinson SE . Plasma sex hormone concentrations and subsequent risk of breast cancer among women using post-menopausal hormones . J Natl Cancer Inst . 2005;97:595–602
  38. Shanafelt TD , Barton LB , Adjei AA , Loprinzi CL . Patho-physiology and treatment of hot flashes . Mayo Clin Proc . 2002;77:1207–1218
  39. Gold EB , Sternfeld B , Kelsey JL , Brown C , Mouton C , Reame N , et al.   Relation of demographic and lifestyle factors to symptoms in a multiracial ethnic population of women 40–55 years of age . Am J Epidemiol . 2000;152:463–473
  40. MacLennan A , Lester S , Moore V . Oral estrogen replacement therapy versus placebo for hot flushes (Cochrane Review) . Cochrane Database Syst Rev . 2001;1:CD002978
  41. MacLennan AH , MacLennan A , Wenzel S , Chambers HM , Eckert K . Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial . Med J Aust . 1993;159:102–106
  42. Loh FH , Chen LH , Yu SL , Jorgensen LN . The efficacy of two dosages of a continuous combined hormone replacement regimen . Maturitas . 2002;41:123–131
  43. Baerug U , Winge T , Nordland G , et al.   Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? . Climacteric . 1998;1:219–228
  44. Schurmann R , Holler T , Benda N . Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens . Climacteric . 2004;7:189–196
  45. Speroff L , Symons J , Kempfert N , Rowan J , for the Femhrt Study Investigators  . The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms . Menopause . 2000;7:383–390
  46. Greendale GA , Reboussin BA , Slone S , Wasilauskas C , Pike MC , Ursin G . Postmenopausal hormone therapy and change in mammographic density . J Natl Cancer Inst . 2003;95:30–37
  47. McTiernan A , Martin CF , Peck JD , et al.   Estrogen-plusprogestin use and mammographic density in postmenopausal women: women's health initiative randomized trial . J Natl Cancer Inst . 2005;97:1366–1376
  48. Lundstrom E , Wilczek B , von Palffy Z , Soderqvist G , von Schoultz B . Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens . Climacteric . 2001;4:42–48
  49. Sendag F, Cosan Terek M, Ozsener S, Oztekin K, Bilgin O, Bilgen I, et al. Mammographic density changes during different postmenopausal hormone replacement therapies . Fertil Steril . 2001;76:445–450
  50. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Vlachou S, Creatsa M, Panoulis KP, et al. The effect of low-dose hormone therapy on mammographic breast density . Maturitas . 2006;54:78–85
  51. Conner P , Svane G , Azavedo E , et al.   Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy . Fertil Steril . 2004;81:1617–1623
  52. Lundstrom E , Soderqvist G , Svane G , et al.   Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study . Fertil Steril . 2006;85:989–995
  53. Junkermann H , von Holst T , Lang E , Rakov V . Influence of different HRT regimens on mammographic density . Maturitas . 2005;50:105–110

PII: S1028-4559(07)60006-0

doi:10.1016/S1028-4559(07)60006-0

Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 2 , Pages 127-134, June 2007

Article Tools